Limits...
Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experience.

Heudel P, El Karak F, Ismaili N, Droz JP, Flechon A - BMC Urol (2009)

Bottom Line: After a median follow-up of 31.7 months, median overall survival was 19 months.Two patients presented with stage II, one with stage III and eight with stage IV disease All 5 patients who had node positive metastases and treated with radical surgery and adjuvant chemotherapy relapsed and had a disease free survival of 9.6 months.Adjuvant chemotherapy might have a questionable efficacy and the optimal treatment strategy is yet to be defined.

View Article: PubMed Central - HTML - PubMed

Affiliation: Léon Bérard Cancer Center, 28 Rue Laennec, 69008 Lyon, France. pierreheudel@yahoo.fr

ABSTRACT

Background: Micropapillary bladder cancer is a rare and aggressive variant of urothelial carcinoma. A retrospective review of our experience in management of patients with muscle-invasive or metastatic micropapillary bladder cancer was performed to better define the behavior of this disease.

Methods: We reviewed the records of the 11 patients with micropapillary bladder cancer who were evaluated and treated at Léon Bérard Cancer Center between 1994 and 2007, accounting for 1,2% of all urothelial tumors treated in this institution.

Results: Mean patients age was 60 years. The majority of patients (72%) were diagnosed after 2004. After a median follow-up of 31.7 months, median overall survival was 19 months. Two patients presented with stage II, one with stage III and eight with stage IV disease All 5 patients who had node positive metastases and treated with radical surgery and adjuvant chemotherapy relapsed and had a disease free survival of 9.6 months.

Conclusion: Micropapillary bladder cancer is probably an underreported variant of urothelial carcinoma associated with poor prognosis. Adjuvant chemotherapy might have a questionable efficacy and the optimal treatment strategy is yet to be defined.

Show MeSH

Related in: MedlinePlus

Overall survival of 11 patients with micropapillary muscle invasive or metastatic bladder cancer. Description: represents the Overall survival of 11 patients with micropapillary muscle invasive or metastatic bladder cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2713271&req=5

Figure 2: Overall survival of 11 patients with micropapillary muscle invasive or metastatic bladder cancer. Description: represents the Overall survival of 11 patients with micropapillary muscle invasive or metastatic bladder cancer.

Mentions: At a median follow up of 31.7 months, 9 patients have died. Disease free survival was 9,6 months. One and two-years survival were 64% and 36% respectively and median survival was 19 months. Progression free survival is illustrated in figure 1 and overall survival in figure 2.


Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experience.

Heudel P, El Karak F, Ismaili N, Droz JP, Flechon A - BMC Urol (2009)

Overall survival of 11 patients with micropapillary muscle invasive or metastatic bladder cancer. Description: represents the Overall survival of 11 patients with micropapillary muscle invasive or metastatic bladder cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2713271&req=5

Figure 2: Overall survival of 11 patients with micropapillary muscle invasive or metastatic bladder cancer. Description: represents the Overall survival of 11 patients with micropapillary muscle invasive or metastatic bladder cancer.
Mentions: At a median follow up of 31.7 months, 9 patients have died. Disease free survival was 9,6 months. One and two-years survival were 64% and 36% respectively and median survival was 19 months. Progression free survival is illustrated in figure 1 and overall survival in figure 2.

Bottom Line: After a median follow-up of 31.7 months, median overall survival was 19 months.Two patients presented with stage II, one with stage III and eight with stage IV disease All 5 patients who had node positive metastases and treated with radical surgery and adjuvant chemotherapy relapsed and had a disease free survival of 9.6 months.Adjuvant chemotherapy might have a questionable efficacy and the optimal treatment strategy is yet to be defined.

View Article: PubMed Central - HTML - PubMed

Affiliation: Léon Bérard Cancer Center, 28 Rue Laennec, 69008 Lyon, France. pierreheudel@yahoo.fr

ABSTRACT

Background: Micropapillary bladder cancer is a rare and aggressive variant of urothelial carcinoma. A retrospective review of our experience in management of patients with muscle-invasive or metastatic micropapillary bladder cancer was performed to better define the behavior of this disease.

Methods: We reviewed the records of the 11 patients with micropapillary bladder cancer who were evaluated and treated at Léon Bérard Cancer Center between 1994 and 2007, accounting for 1,2% of all urothelial tumors treated in this institution.

Results: Mean patients age was 60 years. The majority of patients (72%) were diagnosed after 2004. After a median follow-up of 31.7 months, median overall survival was 19 months. Two patients presented with stage II, one with stage III and eight with stage IV disease All 5 patients who had node positive metastases and treated with radical surgery and adjuvant chemotherapy relapsed and had a disease free survival of 9.6 months.

Conclusion: Micropapillary bladder cancer is probably an underreported variant of urothelial carcinoma associated with poor prognosis. Adjuvant chemotherapy might have a questionable efficacy and the optimal treatment strategy is yet to be defined.

Show MeSH
Related in: MedlinePlus